A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.
about
Update on treatment of light chain amyloidosisRationale, application and clinical qualification for NT-proBNP as a surrogate end point in pivotal clinical trials in patients with AL amyloidosisA study of implanted cardiac rhythm recorders in advanced cardiac AL amyloidosis.Bortezomib, melphalan, and prednisolone combination chemotherapy for newly diagnosed light chain (AL) amyloidosis.First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ DysfunctionImmunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.Life-saving implantable cardioverter defibrillator therapy in cardiac AL amyloidosis.Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III).Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo stagingClinical profile and treatment outcome of older (>75 years) patients with systemic AL amyloidosis.Stem cell transplantation compared with melphalan plus dexamethasone in the treatment of immunoglobulin light-chain amyloidosis.Ventricular fibrillation after bortezomib therapy in a patient with systemic amyloidosis.Long-term event-free and overall survival after risk-adapted melphalan and SCT for systemic light chain amyloidosis.Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis.Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach.New insights and modern treatment of AL amyloidosis.Future directions in the clinical management of amyloid light-chain amyloidosis.Natural history and therapy of AL cardiac amyloidosis.Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T.Lenalidomide/melphalan/dexamethasone in newly diagnosed patients with immunoglobulin light chain amyloidosis: results of a prospective phase 2 study with long-term follow up.Cardiac amyloidosis: where are we today?Recent advances in the management of AL Amyloidosis.Novel strategies for the diagnosis and treatment of cardiac amyloidosis.New and developing therapies for AL amyloidosis.Immunoglobulin light chain amyloidosis: 2016 update on diagnosis, prognosis, and treatment.Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.Heart transplantation in cardiac amyloidosis.Bortezomib-dexamethasone versus high-dose melphalan for Japanese patients with systemic light-chain (AL) amyloidosis: a retrospective single-center study.Short- and long-term outcomes of AL amyloidosis patients admitted into intensive care units.Congestive heart failure: a case of protein misfoldingOutcome of patients with systemic light chain amyloidosis with concurrent renal and cardiac involvement.Macroglosia: amyloidosis misdiagnosed as angio-oedema.Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.Different patterns of left ventricular rotational mechanics in cardiac amyloidosis-results from the three-dimensional speckle-tracking echocardiographic MAGYAR-Path Study.Light chain amyloidosis: the heart of the problem.Treating advanced cardiac damage in light chain amyloidosis: still an unmet need.Auto-SCT improves survival in systemic light chain amyloidosis: a retrospective analysis with 14-year follow-up.
P2860
Q26829735-B7473FF9-8D1F-4F37-ABFC-1B92B7F2084CQ28069975-8F39D028-B03B-4BDE-903E-F9AA9CE87FBBQ33165133-895BB1B8-3D50-4ADE-89ED-8AC2BC16C604Q33417805-2FF8ED25-8649-4071-BC9B-13AAA377F1ADQ33795363-30E0FF5E-5C85-4794-A69B-BD8EFCE82017Q34448455-E91A7807-5D7E-4972-8443-59BAE8189FE0Q34768284-976278A8-5CF4-4F17-BBA8-88104E416655Q36036322-00433067-5BF3-448F-A66B-433C29B8245BQ36165179-024F0F01-4DE9-4F50-AE8A-E5F5098DEE1CQ36288753-4D505F92-E65E-4D60-9A2D-47F4012B977CQ36779759-39D6B3D0-BE81-4930-BF2C-024B2D4DBCCFQ37059137-7E59C2DB-3B06-4A9A-B16B-9E9DAB53110EQ37247207-750615BD-8C3D-4685-9803-8374BC7755B9Q37570615-F157F032-7207-4569-B8FB-8DBE1D2EBF2BQ37624857-DC01E397-2FE1-4056-82F9-BF8EA3F74F9DQ37676296-5BCC3F36-4763-4F6C-9152-ADE9358D8AD2Q38136576-C1C7BDA1-52B8-428D-9431-8F8EC1E0C9E3Q38172998-D63A6ED5-3E47-4CA8-A4DC-D7E89408E778Q38275212-9635D909-F965-4D83-A7E3-011BA9B57813Q38370866-3E49A8E1-63D6-4D06-9EEF-DF3085496B35Q38376616-E6154C56-E2F8-45DC-B2C5-F83597FF914FQ38528406-608828CB-BC28-44EC-9032-41FCDBB931E8Q38613822-86FAFB66-07F1-4F63-AEDA-F9DFA7D196BCQ38614967-3D8EC7B1-C0DB-43A1-9455-A7B54DF89929Q38779623-6F7CD8C2-B30B-4F2F-8AAD-7B714E0F91E7Q38928383-F458B571-5F50-449C-B1A6-C5EC8BE764A8Q38959241-A235F29F-12CA-4C79-9287-273741C76336Q39024208-79077B5E-FD15-404F-AF8C-AECAB2704DD9Q39172346-DB933B12-80C0-4587-8B4F-29B1F7237BBAQ40480703-C4DD17AA-8FF5-4953-86BF-0767829EFC56Q40705462-9DC3D740-4295-480F-BB8A-3DE3E2567B73Q40915694-3B958312-9A89-4543-AA87-03EDB87CF0E6Q40973226-D37FE0CF-7FCE-4B30-9241-4907D63EEECAQ40982846-83FC0D1F-6777-4021-9292-E66EFEC88A0CQ41593651-FD407D89-45EF-4E6D-8B33-2A1AD551397CQ41714209-8B617048-86A3-4D50-9A1D-7553D3EEF58BQ42226402-CE6151C5-21F5-471C-A398-3847676C67D5Q42958777-DF2C7325-E0CA-4825-BB03-056C1DA8C77BQ43134938-EB80928D-8FBE-4B18-A25F-B88FFCF6D86DQ44060632-71E85A83-8660-40B7-A6C6-1293F51F4FF9
P2860
A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
A European collaborative study ...... diac stage III AL amyloidosis.
@en
A European collaborative study ...... diac stage III AL amyloidosis.
@nl
type
label
A European collaborative study ...... diac stage III AL amyloidosis.
@en
A European collaborative study ...... diac stage III AL amyloidosis.
@nl
prefLabel
A European collaborative study ...... diac stage III AL amyloidosis.
@en
A European collaborative study ...... diac stage III AL amyloidosis.
@nl
P2093
P50
P1433
P1476
A European collaborative study ...... rdiac stage III AL amyloidosis
@en
P2093
Andrea Foli
Ashutosh D Wechalekar
Darren Foard
Julian D Gillmore
Lisa Rannigan
Philip N Hawkins
Thirusha Lane
Ute Hegenbart
P304
P356
10.1182/BLOOD-2012-12-473066
P407
P50
P577
2013-03-11T00:00:00Z